CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

Abstract excerpt

BACKGROUND: ), with the goal of lifelong control of angioedema attacks after a single dose. METHODS: In this phase 1 dose-escalation portion of a combined phase 1-2 trial of NTLA-2002 in adults with hereditary angioedema, we administered NTLA-2002 at a single dose of 25 mg, 50 mg, or 75 mg. The primary end points were the safety and side-effect profile of NTLA-2002 therapy. Secondary and exploratory end points...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to Complement system in diseases
• Share to Hemophilia Treatment and Research